Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Neoadjuvant Therapies for HER2+ Breast Cancer
Interventions: DRUG: investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)|DRUG: investigator-selected taxane/trastuzumab/pertuzumab (THP)
Sponsor: Guangdong Provincial People's Hospital